NCT01758328View on ClinicalTrials.gov

Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

March 17, 2025

Study Completion Date

March 17, 2025

Conditions

Multiple Myeloma

Interventions

DRUG

busulfan

DRUG

melphalan

DRUG

fludarabine

BIOLOGICAL

anti-thymocyte globulin (ATG)

PROCEDURE

a T cell depleted stem cell transplant

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01758328 - Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter